Spotlight
Video

Is nindetanib a new agent worthy of becoming a new treatment for advanced NSCLC?

cancergrace has 795 videos Subscribe Here

Loading........
Description: http://cancerGRACE.org/...

Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nindetanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.

GRACEcastUC 139 Lung
Shared By : cancergrace
Posted on : 06/26/13
Added : 4 years ago
Category : General